Drug Trial Radar · NCT05238922
Study of INCB123667 in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
291
Actual
Start
Jul 5, 2022
Primary completion
Jul 27, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Feb 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of interest. Each part will comprise a dose escalation portion (Parts 1a and 2a, respectively) and a dose-expansion portion (Parts 1b and 2b, respectively).
Conditions
- Solid Tumors
Interventions
INCB0123667Drug
25 mg tablets
PalbociclibDrug
Palbociclib will be administered at protocol defined dose.
BevacizumabDrug
Bevacizumab will be administered at protocol defined dose.
OlaparibDrug
Olaparib will be administered at protocol defined dose.
PaclitaxelDrug
Paclitaxel will be administered at protocol defined dose.
RibociclibDrug
Ribociclib will be administered at protocol defined dose.
FulvestrantDrug
Fulvestrant will be administered at protocol defined dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1A : Occurrence of Dose Limiting Toxicities (DLTs)Time frame: Up to Day 28
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 12 months
- Number of Participants with Dose Interruptions due to TEAETime frame: Up to 12 months
- Number of Participants who Undergo Dose Reductions due to TEAETime frame: Up to 12 months
- Number of Participants Discontinue study due to TEAETime frame: Up to 12 months
Locations
41 sites in 8 countries. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California
City of Hope-Lennar Foundation Cancer Center
Irvine, California
Valkyrie Clinical Trials
Los Angeles, California
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree, Colorado
Yale Cancer Center
New Haven, Connecticut
Mount Sinai Medical Center Comprehensive Cancer Center
Miami Beach, Florida
Emory University
Atlanta, Georgia
Memorial Sloan Kettering Cancer Center
New York, New York
New York Presbyterian/Weill Cornell
New York, New York
Ny Cancer and Blood Specialists
Shirley, New York
Carolina Bio-Oncology Institute, Pllc
Huntersville, North Carolina
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Cancer Institute Cancer Services
Pittsburgh, Pennsylvania
Allegheny Health Network
Pittsburgh, Pennsylvania
Tennessee Oncology
Nashville, Tennessee
Texas Oncology-Fort Worth South Henderson
Fort Worth, Texas
Virginia Cancer Institute
Fairfax, Virginia
University of Wisconsin
Madison, Wisconsin
Institut Bergonie
Bordeaux, France
Centre Leon Berard
Lyon, France
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy
Istituto Nazionale Tumori Irccs Fondazione Pascale
Naples, Italy
Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore
Rome, Italy
Irccs Istituto Clinico Humanitas
Rozzano, Italy
Centro Ricerche Cliniche Di Verona
Verona, Italy
Aichi Cancer Center Hospital
Aichi, Japan
National Cancer Center Hospital East
Chiba-ken, Japan
Saitama Medical University International Medical Center
Hidaka-shi, Japan
National Cancer Center Hospital
Tokyo, Japan
The Cancer Institute Hospital of Jfcr
Tokyo, Japan
Netherlands Cancer Institute Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands
Erasmus Medical Center
Rotterdam, Netherlands
Panoncology Trials Pan American Center For Oncology Trials, Llc
Rio Piedras, Puerto Rico
Oncological Institute of Southern Switzerland
Bellinzona, Switzerland
Inselspital Universitatsklinik Fur Medizinische Onkologie
Bern, Switzerland
Centre Hospitalier Universitaire Vaudois (Chuv)
Lausanne, Switzerland
Guys Hospital
London, United Kingdom
Imperial College Healthcare Nhs Trust - Hammersmith Hospital
London, United Kingdom
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.